Eli Lilly

LLY

Market cap $963B

Both of these stocks are growing by leaps and bounds. MercadoLibre boasts a cohesive ecosystem that is driving revenue and profits forward.

A major U.S. chipmaker got a boost from speculation that it could win a new Big Tech customer, while a high-flying pharmaceutical stock reversed some of its recent gains.

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Market expert Len Yaffee says it would be increasingly difficult for Eli Lilly (NYSE: LLY) to push higher from current levels – at least in the near-term. LLY shares have been standout performers in 2025 – riding the wave of investor enthusiasm around its obesity and diabetes drugs (Zepbound and Mounjaro).

Eli Lilly's valuation may suggest that its market-beating days are behind it. However, the pharmaceutical giant still has significant momentum.

Len Yaffee, Kessef Capital, join 'Fast Money' to talk Amgen's obesity drug, Eli Lilly's current stock action, and much more.

Eli Lilly's stock is surging amid a flurry of AI deals. Our proprietary Zacks Rank system confirms the trend.

Eli Lilly stock has soared in the triple digits over three years. Investors are excited about the company's portfolio of weight loss drugs, which has generated blockbuster revenue.

HP (HPQ) shares dropped 6% after issuing a weak forecast and announcing up to 6,000 job cuts despite beating quarterly earnings estimates. The Trump administration secured a 71% Medicare discount on Ozempic and Wegovy (NVO), expected to save taxpayers $12 billion starting in 2027.

In the last part of November 2025, Eli Lilly and Company NYSE: LLY shattered a historic ceiling. The Indianapolis-based drugmaker became the first pharmaceutical company to reach a market capitalization of $1 trillion.